AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Recruiting

Phase 2

AlloNK® & RituximabAlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

Sponsor:

Artiva Biotherapeutics, Inc.

Code:

NCT06991114

Conditions

Refractory Rheumatoid Arthritis (RA)

Idiopathic Inflammatory Myopathies (IIMs)

Systemic Sclerosis (SSc)

Rheumatoid Arthritis (RA

IIM

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Allogeneic NK Cells

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-12. This information was provided to ClinicalTrials.gov by Artiva Biotherapeutics, Inc. on 2025-10-20.